-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Downgrades Verve Therapeutics to Market Perform, Lowers Price Target to $13.5

Benzinga·06/27/2025 17:09:58
Listen to the news
BMO Capital analyst Kostas Biliouris downgrades Verve Therapeutics (NASDAQ:VERV) from Outperform to Market Perform and lowers the price target from $20 to $13.5.